Poster exhibition
SARS-CoV-2

Programme

• • Poster
  • P 230

  SARS-CoV-2 ORF3c suppresses the induction of IFN-β

  • Martin Müller (Tuebingen / DE)

   SARS-CoV-2, Viral pathogenesis and persistence
• • Poster
  • P 231

  Pim-kinase inhibitors as antivirals against SARS-CoV-2

  • Dr. Mirco Glitscher (Langen / DE)

   Host cell factors and modulation, SARS-CoV-2
• • Poster
  • P 232

  Functional impact of Spike mutations in SARS-CoV-2 Omicron lineages

  • Chiara Pastorio (Ulm / DE)

   SARS-CoV-2, Virus receptors and entry
• • Poster
  • P 233

  Identification of SARS-CoV-2 spike mutations that confer resistance towards therapeutic antibodies, using molnupiravir-based mutagenesis

  • Priya Kumar (Goettingen / DE)

   Antiviral therapy and resistance, SARS-CoV-2
• • Poster
  • P 234

  The host-targeted MEK1/2-inhibitor ATR-002 (Zapnometinib) acts antiviral against SARS-CoV-2 and synergistically potentiates the antiviral effect of direct-acting anti-SARS-CoV-2 drugs

  • Benjamin Ambrosy (Muenster / DE)

   Host cell factors and modulation, SARS-CoV-2
• • Poster
  • P 235

  Heterologous SARS-CoV-2 delta breakthrough infection elicits broader and more durable neutralizing antibody response than (non-breakthrough) infection

  • Sebastian Einhauser (Regensburg / DE)

   Epidemiology and public health, SARS-CoV-2
• • Poster
  • P 236

  Identification of β-catenin/CBP as a host factor for SARS-CoV-2 using machine learning on large scale perturbation screens

  • Maximilian A. Kelch (Frankfurt / DE)

   Antiviral therapy and resistance, SARS-CoV-2
• • Poster
  • P 237

  Molecular analyses of clinical isolates and recombinant SARS-CoV-2 carrying B.1 and B.1.617.2 spike mutations suggest a potential role of non-spike mutations in infection kinetics

  • Maximilian A. Kelch (Frankfurt / DE)

   SARS-CoV-2, Viral pathogenesis and persistence
• • Poster
  • P 238

  A virus-free reporter enzyme assay to identify antiviral drug candidates against SARS-CoV-2 spike protein mediated cell-cell fusion

  • Nica Classen (Muenster / DE)

   Antiviral therapy and resistance, SARS-CoV-2
• • Poster
  • P 239

  Inhibition of CTP synthetase synergizes with the active metabolite of Molnupiravir to block SARS-CoV-2 replication

  • Dr. Kim Maren Stegmann (Goettingen / DE)

   Antiviral therapy and resistance, SARS-CoV-2
• • Poster
  • P 240

  SARS-CoV-2 productively infects human hepatocytes and induces cell death

  • Cho-Chin Cheng (Munich / DE)

   SARS-CoV-2, Viral pathogenesis and persistence
• • Poster
  • P 241

  Egyptian fruit bat (Rousettus aegyptiacus) susceptibility to SARS-CoV-2 infection – different susceptibility and pathogenesis upon respiratory and oral infection

  • Dr. Björn-Patrick Mohl (Greifswald / DE)

   Emerging viruses and zoonosis, SARS-CoV-2
• • Poster
  • P 242

  Antigenic distances between emerging SARS-CoV-2 variants of concern

  • Mariana Gonzalez Hernandez (Hannover / DE)

   Emerging viruses and zoonosis, SARS-CoV-2
• • Poster
  • P 243

  The Acid Ceramidase is a host factor of SARS-CoV-2

  • Nina Geiger (Wuerzburg / DE)

   Antiviral therapy and resistance, SARS-CoV-2
• • Poster
  • P 244

  Identification of herbal teas and their compounds eliciting antiviral activity against SARS-CoV-2 in vitro

  • Prof. Dr. Mirko Trilling (Essen / DE)

   Antiviral therapy and resistance, SARS-CoV-2
• • Poster
  • P 245

  Sensitivity to SARS-CoV-2 Omicron variant BA.2 infection observed in Golden Syrian Hamsters – defining the minimal infectious dose

  • Dr. Claudia Blaurock (Greifswald / DE)

   Emerging viruses and zoonosis, SARS-CoV-2
• • Poster
  • P 246

  SARS-CoV-2 cell-to-cell transmission, as opposed to cell-free infection, evades from cell-intrinsic innate and humoral immunity

  • Saskia Stenzel (Berlin / DE)

   Innate immunity, SARS-CoV-2
• • Poster
  • P 247

  Omicron-induced interferon signalling prevents influenza A virus infection

  • Prof. Dr. Denisa Bojkova (Frankfurt / DE)

   Innate immunity, SARS-CoV-2
• • Poster
  • P 248

  The N-Acylethanolamine acid amidase is a SARS-CoV-2 host factor

  • Veronica La Rocca (Pisa / IT)

   Antiviral therapy and resistance, SARS-CoV-2
• • Poster
  • P 249

  The role of SARS-CoV-2 ORF3a in host translational and immune signaling pathways

  • Priya Baral (Munich / DE)

   SARS-CoV-2, Viral replication strategies 1 (RNA viruses)
• • Poster
  • P 251

  SARS-CoV-2 variants show different host cell proteome profiles with delayed immune response activation in Omicron-infected cells

  • Melinda Metzler (Frankfurt / DE)

   Innate immunity, SARS-CoV-2
• • Poster
  • P 252

  Prevalence of SARS-CoV-2 in companion animals

  • Zahra Ghodratian (Frankfurt / DE)

   Emerging viruses and zoonosis, SARS-CoV-2
• • Poster
  • P 253

  Cellular electrical impedance to profile SARS-CoV-2 fusion inhibitors and to assess the fusogenic potential of spike mutants

  • Emiel Vanhulle (Leuven / BE)

   SARS-CoV-2, Virus receptors and entry
• • Poster
  • P 254

  The impact of N-butyldeoxynojirimycin and 1-deoxymannojirimycin on SARS-CoV-2 S1 subunit and angiotensin-converting enzyme 2 interaction in intestinal epithelial cells

  • Marianne El Khoury (Hannover / DE)

   Antiviral therapy and resistance, SARS-CoV-2
• • Poster
  • P 256

  In vitro selection of a carboxyterminally located mutation within the protease NSP5 of SARS-CoV-2 confers resistance towards Nirmatrelvir

  • Antje Dickmanns (Goettingen / DE)
  • Dr. Kim Maren Stegmann (Goettingen / DE)

   Antiviral therapy and resistance, SARS-CoV-2
• • Poster
  • P 258

  Development and characterization of human kidney derived cell models for SARS-CoV-2 infections

  • Marco Bechtel (Frankfurt / DE)

   Host cell factors and modulation, SARS-CoV-2
• • Poster
  • P 259

  Identification of cellular factors involved in SARS-CoV-2 replication and cytotoxicity using a genome-wide CRISPR-Cas9 knockout survival screen

  • Dr. Gaia Lupoli (Munich / DE)

   Host cell factors and modulation, SARS-CoV-2
• • Poster
  • P 260

  Generation of SARS-CoV-2 Bacmids containing large fragments of Omicron as a new strategy to analyse its pathology and virulence

  • Marius Wrage (Erlangen / DE)

   SARS-CoV-2, Viral replication strategies 1 (RNA viruses)
• • Poster
  • P 261

  Interferon signalling in monocytes exposed to different SARS-CoV-2 variants

  • Joshua D. Kandler (Frankfurt / DE)

   Innate immunity, SARS-CoV-2
• • Poster
  • P 262

  Establishment of a mathematical model for the analysis of factors influencing the intracellular replication of SARS-CoV-2 and related Coronaviruses

  • Simon Thomas Herrmann (Bochum / DE)

   SARS-CoV-2, Structure, assembly, egress
• • Poster
  • P 263

  Impact of human ACE2 N-glycosylation on SARS-CoV-2 spike-mediated infection

  • Sabrina Noettger (Ulm / DE)

   SARS-CoV-2, Structure, assembly, egress
• • Poster
  • P 264

  The SARS-CoV-2 macrodomain1 and its role in ADP-ribose binding and hydrolysis

  • Sarah Knapp (Aachen / DE)

   Innate immunity, SARS-CoV-2
• • Poster
  • P 265

  A live attenuated SARS-CoV-2 vaccine candidate confers superior protection against virus transmission

  • Ricardo Martin Vidal (Berlin / DE)

   SARS-CoV-2, Vaccines
• • Poster
  • P 266

  Bivalent BNT162b2mRNA original/Omicron BA.4-5 booster vaccination – adverse reactions and inability to work compared to the monovalent COVID-19 booster

  • Isabell Wagenhäuser (Wuerzburg / DE)

   SARS-CoV-2, Vaccines
• • Poster
  • P 267

  β-Propiolactone (BPL)-inactivation of SARS-Co-V-2 – in vitro validation with focus on saliva from COVID-19 patients for scent dog training

  • Veronika Pilchová (Hannover / DE)

   Emerging viruses and zoonosis, SARS-CoV-2
• • Poster
  • P 268

  Longitudinal surveillance of COVID-19 in medical and dental students between January 2021 and February 2023 in Munich, Germany

  • Dr. Paul Robin Wratil (Munich / DE)

   Epidemiology and public health, SARS-CoV-2
• • Poster
  • P 269

  TMPRSS2 is essential for SARS-CoV-2 Beta and Omicron infection in mice

  • Dr. Kristin Metzdorf (Braunschweig / DE)

   SARS-CoV-2, Virus receptors and entry